智通财经APP获悉，药捷安康-B(02617)涨超11%，截至发稿，涨11.37%，报11.17港元，成交额1.03亿港元。
消息面上，9月18日晚，药捷安康公告，公司核心产品替恩戈替尼(捷恩泰®， Tinengotinib, TT-00420)联合新型内分泌治疗(NHT)用于经治后进展的转移性去势抵抗性前列腺癌(mCRPC)中国II期临床试验，于近日完成首例患者给药。
此外，9月17日，药捷安康宣布，其核心产品捷恩泰®（替恩戈替尼片）首批产品正式从商业渠道发货，发往全国各地药房，捷恩泰®正式开启全国商业化供应，标志着这款全球首个解决FGFR抑制剂耐药的胆管癌靶向药即将陆续抵达全国各地患者手中。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.